GOP Hemp Dispute Delays Spending Bill

An internal dispute within the Republican Party over hemp-derived THC products is slowing the progress of a crucial government funding bill. The Senate’s proposed funding legislation intends to delay the prohibition of most hemp-derived THC products until December 11, which is a month later than previously expected. This amendment, advocated by the White House, surprised some senators.

Senator Ted Budd from North Carolina, along with several other Republicans, opposes this delay. They are blocking the bill’s passage, seeking a vote on an amendment to remove the delay. Their main concern is the accessibility of hemp-derived THC products to children. Despite this opposition, the administration has been clear about its stance on the matter for several months. In April, President Trump called for Congress to revise the law so that full-spectrum CBD products remain available while restricting harmful products.

During discussions in June about the Agriculture, Rural Development, and FDA funding package, the Office of Management and Budget highlighted the administration’s stance. They expressed the desire to work with Congress to redefine hemp-derived cannabinoid products. The aim is to ensure public access to beneficial CBD products while preventing the sale of potentially dangerous items.

The controversy centers around a law enacted last year that redefined hemp to close what was referred to as the ‘hemp loophole.’ The 2018 Farm Bill had removed hemp from the list of controlled substances. However, the lack of precise federal regulation allowed companies to produce high-THC products. These products, including edibles and beverages, have become popular and are widely available beyond licensed dispensaries. They are sold in various locations like gas stations and major retailers, often with packaging that can appeal to children. The new legislation aims to limit legal hemp products to a maximum of 0.4 milligrams of total THC per container and similar cannabinoids. The regulation was scheduled to take effect on November 12 but will be delayed should the bill pass. This policy excludes synthetic cannabinoids not derivable from Cannabis sativa L. plants, targeting illegal imports from regions like China.

Additionally, healthcare news involves the Senate’s vote on holding Dr. Anthony Fauci in contempt of Congress following his refusal to answer questions by invoking the Fifth Amendment. The potential legal risks for Fauci depend on whether the Department of Justice pursues the matter.

In related news, Dr. Erica Schwartz has been confirmed as the new director of the CDC after a Senate vote, ending a nearly year-long vacancy. Tim Kaine was noted as the sole Democrat supporting her confirmation.